Viking Therapeutics, Inc.
VKTX
$23.94
$0.341.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -35.42M | -24.94M | -22.25M | -27.36M | -24.61M |
| Total Depreciation and Amortization | 110.00K | 87.00K | 75.00K | 74.00K | 74.00K |
| Total Amortization of Deferred Charges | 24.00K | 24.00K | 18.00K | 28.00K | 26.00K |
| Total Other Non-Cash Items | 1.65M | 3.90M | 1.66M | 5.17M | 1.39M |
| Change in Net Operating Assets | 2.46M | -1.03M | -8.01M | 15.95M | 5.48M |
| Cash from Operations | -31.18M | -21.96M | -28.51M | -6.13M | -17.64M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.58M | 25.90M | -126.06M | -459.79M | 35.73M |
| Cash from Investing | 6.58M | 25.90M | -126.06M | -459.79M | 35.73M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.00M | 2.52M | 2.91M | 648.14M | 188.00K |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -42.10M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.00M | 2.52M | 2.91M | 606.04M | 188.00K |
| Foreign Exchange rate Adjustments | -74.00K | -29.00K | 3.00K | -48.00K | 50.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.67M | 6.43M | -151.66M | 140.06M | 18.33M |